Cover Image
市場調查報告書

甲狀腺機能低下症:開發中產品分析

Hypothyroidism - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360910
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺機能低下症:開發中產品分析 Hypothyroidism - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 29 Pages
簡介

本報告提供甲狀腺機能低下症治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

Hypothyroidism概要

治療藥的開發

  • 開發中產品的概要

Hypothyroidism:企業開發中的治療藥

Hypothyroidism:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

Hypothyroidism:企業開發中的產品

Hypothyroidism治療藥的開發企業

  • Synthonics, Inc.
  • Titan Pharmaceuticals, Inc.

Hypothyroidism:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

Hypothyroidism:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9326IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H1 2017, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.

Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 1 and 5 respectively.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypothyroidism - Overview
    • Hypothyroidism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hypothyroidism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypothyroidism - Companies Involved in Therapeutics Development
    • Genexine Inc
    • Synthonics Inc
    • Titan Pharmaceuticals Inc
  • Hypothyroidism - Drug Profiles
    • (levothyroxine sodium + liothyronine sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCT-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-30 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levothyroxine sodium SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liothyronine sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liothyronine sodium SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liothyronine sodium SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypothyroidism - Dormant Projects
  • Hypothyroidism - Product Development Milestones
    • Featured News & Press Releases
      • Nov 16, 2015: Titan Pharmaceuticals Adds Proneura Implant For Hypothyroidism To Product Development Pipeline
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypothyroidism, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hypothyroidism - Pipeline by Genexine Inc, H1 2017
  • Hypothyroidism - Pipeline by Synthonics Inc, H1 2017
  • Hypothyroidism - Pipeline by Titan Pharmaceuticals Inc, H1 2017
  • Hypothyroidism - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Hypothyroidism, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top